Paradoxical inhibition of cellular protein expression by proteasome inhibitors

Proteasome inhibitors are used as anticancer drugs, however, the precise mechanisms of their selective activity against cancer cells are not understood well. While proteasome inhibitors stabilize the majority of cellular proteins through inhibition of proteasome activity, they also paradoxically dow...

Full description

Bibliographic Details
Main Author: Gartel Andrei L.
Format: Article
Language:English
Published: De Gruyter 2012-12-01
Series:Biomolecular Concepts
Subjects:
arf
npm
Online Access:https://doi.org/10.1515/bmc-2012-0029
id doaj-3c6e94ab47334f25950d6ca2ec361604
record_format Article
spelling doaj-3c6e94ab47334f25950d6ca2ec3616042021-09-05T20:42:33ZengDe GruyterBiomolecular Concepts1868-50211868-503X2012-12-013659359510.1515/bmc-2012-0029Paradoxical inhibition of cellular protein expression by proteasome inhibitorsGartel Andrei L.0Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USAProteasome inhibitors are used as anticancer drugs, however, the precise mechanisms of their selective activity against cancer cells are not understood well. While proteasome inhibitors stabilize the majority of cellular proteins through inhibition of proteasome activity, they also paradoxically downregulate several other proteins. We recently discovered that proteasome inhibitors suppress mRNA and protein expression of FOXM1, NPM, and ARF proteins that are involved in cancer. We postulated that proteasome inhibitors preferentially stabilize negative regulators of transcription of these genes, which overrides their protein stabilization. These data suggest a presence of multiple secondary mechanisms that may regulate transcription, degradation, or localization of cellular proteins after treatment with proteasome inhibitors. Future experiments will identify these mechanisms and additional proteins suppressed by proteasome inhibitors, and will help explain the role of protein suppression by proteasome inhibitors in their anticancer activity.https://doi.org/10.1515/bmc-2012-0029arffoxm1negative regulatornpmtranscription
collection DOAJ
language English
format Article
sources DOAJ
author Gartel Andrei L.
spellingShingle Gartel Andrei L.
Paradoxical inhibition of cellular protein expression by proteasome inhibitors
Biomolecular Concepts
arf
foxm1
negative regulator
npm
transcription
author_facet Gartel Andrei L.
author_sort Gartel Andrei L.
title Paradoxical inhibition of cellular protein expression by proteasome inhibitors
title_short Paradoxical inhibition of cellular protein expression by proteasome inhibitors
title_full Paradoxical inhibition of cellular protein expression by proteasome inhibitors
title_fullStr Paradoxical inhibition of cellular protein expression by proteasome inhibitors
title_full_unstemmed Paradoxical inhibition of cellular protein expression by proteasome inhibitors
title_sort paradoxical inhibition of cellular protein expression by proteasome inhibitors
publisher De Gruyter
series Biomolecular Concepts
issn 1868-5021
1868-503X
publishDate 2012-12-01
description Proteasome inhibitors are used as anticancer drugs, however, the precise mechanisms of their selective activity against cancer cells are not understood well. While proteasome inhibitors stabilize the majority of cellular proteins through inhibition of proteasome activity, they also paradoxically downregulate several other proteins. We recently discovered that proteasome inhibitors suppress mRNA and protein expression of FOXM1, NPM, and ARF proteins that are involved in cancer. We postulated that proteasome inhibitors preferentially stabilize negative regulators of transcription of these genes, which overrides their protein stabilization. These data suggest a presence of multiple secondary mechanisms that may regulate transcription, degradation, or localization of cellular proteins after treatment with proteasome inhibitors. Future experiments will identify these mechanisms and additional proteins suppressed by proteasome inhibitors, and will help explain the role of protein suppression by proteasome inhibitors in their anticancer activity.
topic arf
foxm1
negative regulator
npm
transcription
url https://doi.org/10.1515/bmc-2012-0029
work_keys_str_mv AT gartelandreil paradoxicalinhibitionofcellularproteinexpressionbyproteasomeinhibitors
_version_ 1717785518857519104